Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

FDA clears IND for RP-L401 gene therapy for infantile malignant osteopetrosis

June 30, 2020

Janssen discontinues phase III LOTUS study of ustekinumab in SLE

June 29, 2020

Novartis presents compounds for arthritis

June 26, 2020

Tarapeutics Science patents PI3Kdelta inhibitors

June 22, 2020

FDA approves Cosentyx for active nonradiographic axial spondyloarthritis

June 17, 2020

Ilaris approved in U.S. for active Still's disease

June 17, 2020

Netakimab demonstrates superiority to placebo in second-line psoriatic arthritis

June 17, 2020

Domain Therapeutics' biased PAR2 inhibitors show antiarthritic effects

June 11, 2020

AbbVie reports new phase IIa data on ABBV-3373 in moderate to severe rheumatoid arthritis

June 11, 2020

Modified peptides generate RA-specific CD4+ T cells with lytic properties against APCs

June 11, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...